Skip to main content

REGENXBIO Inc.

RGNX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001590877

In the last 90 days, REGENXBIO Inc. insiders filed 1 open-market purchase and 0 sales; 165 institutions reported holding it in 13F filings for Q2 2026, worth $504.6M in total; no superinvestor holds it.

Q3 2023 vs. Q2 2023

How the institutions holding REGENXBIO Inc. changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of RGNX: Q2 2023 compared with Q3 2023
MeasureQ2 2023Q3 2023Change
Holders167160−7
Shares37.1M37.0M−82.7K (−0.2%)
Value$742.1M$610.3M−$131.8M (−17.8%)

New holders (17)

Institutions that held REGENXBIO Inc. at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to RGNX in Q3 2023
InstitutionSharesValue% of portfolio
D. E. Shaw & Co., Inc.44,628$734.6K0.00%
Squarepoint Ops LLC41,592$684.6K0.00%
Gsa Capital Partners LLP37,668$620.0K0.05%
Marshall Wace, LLP33,249$547.3K0.00%
Two Sigma Investments, LP30,212$497.3K0.00%
XTX Topco Ltd22,019$362.4K0.06%
Comerica Bank16,104$265.1K0.00%
Everence Capital Management Inc11,450$188.0K0.01%
Prentiss Smith & Co Inc11,240$185.0K0.14%
Walleye Capital LLC10,857$178.7K0.00%
Vident Advisory, LLC10,182$167.6K0.01%
Aquatic Capital Management LLC4,100$67.0K0.00%
Annandale Capital, LLC3,617$60.0K0.02%
WR Wealth Planners, LLC135$2.22K0.00%
Huntington National Bank98$1.61K0.00%
GPS Wealth Strategies Group, LLC13$2140.00%
Capital Advisors, Ltd. LLC10$00.00%

Sold out (24)

Institutions that held REGENXBIO Inc. at the end of Q2 2023 and filed for Q3 2023 without it.